Rachna Shroff

University of Arizona
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Purpose: Isocitrate dehydrogenase (IDH) 1/2–isoform inhibitors have clinical efficacy in IDH1/ IDH2- mutated neoplasms. However, primary resistance and secondary resistance limit their therapeutic potential. LY3410738, an oral, brain-penetrant, dual IDH1/IDH2-mutated isoform-selective inhibitor, was designed to overcome resistance. Patients and Methods: This global, multicenter, open-label, phase I study of patients with IDH- mutant solid tumors evaluated LY3410738 as monotherapy (dose escalation) for advanced solid tumors in combination with cisplatin–gemcitabine (CISGEM) for newly diagnosed cholangiocarcinoma or with durvalumab for relapsed/refractory cholangiocarcinoma (dose expansion; NCT04521686). Primary objectives were the maximum tolerated dose, recommended phase II dose, and preliminary antitumor activity. Safety, pharmacokinetics, inhibition of D-2-hydroxyglutarate, and ctDNA were assessed. Results: Overall, 119 patients received LY3410738 alone ( N = 94) or in combination with CISGEM ( N = 19) or durvalumab ( N = 6). No dose-limiting toxicities were observed; the maximum tolerated dose was not determined. Common adverse events included nausea, vomiting, and decreased appetite. Overall response rates of 5.2% and 11.1% and disease control rates of 56.9% and 63.0% were observed for patients with relapsed/refractory IDH1 - or IDH2 -mutant cholangiocarcinoma or IDH1 -mutant glioma, respectively. D-2-hydroxyglutarate normalization was rapid and durable. In dose-expansion cohorts, combination treatments were tolerable, with one dose-limiting toxicity in the durvalumab cohort. LY3410738 plus CISGEM demonstrated a response rate of 42.1%, a median duration of response of 8.1 months, and a median progression-free survival of 10.2 months for patients with newly diagnosed IDH -mutant cholangiocarcinoma. Conclusions: LY3410738 demonstrated largely cytostatic antitumor activity in IDH1- or IDH2- mutated cholangiocarcinoma and IDH1- mutated gliomas. LY3410738 plus CISGEM exhibited favorable antitumor activity in patients with treatment-naïve IDH- mutated cholangiocarcinoma, warranting further exploration as a treatment strategy.

Year:

2025

Supplementary Table S4: Comparison of cytokine gene expression between KRAS mutational subgroups. Median values represent transcript per million (TPM). Only genes with trending or significant differences between subgroups are shown. Bold numbers indicate trending (p

Year:

2025

Purpose: Oncogenic mutations in KRAS have been identified in >85% of pancreatic ductal adenocarcinoma (PDAC) cases, with G12D, G12V, and G12R being the most frequent variants. Using large clinical and genomic databases, this study characterizes prognostic and molecular differences between KRAS variants, focusing on KRAS G12D and KRAS G12R . Experimental Design: PDAC samples were tested using DNA and RNA sequencing. The MAPK activation score and tumor microenvironment were analyzed from RNA expression data. Real-world overall survival (OS) obtained from insurance claims data was calculated from tissue collection to last contact. Significance was determined by χ 2 and Fisher exact tests. Results: A total of 3,755 patients with PDAC harboring KRAS G12D ( n = 1,766), KRAS G12V ( n = 1,294), KRAS G12R ( n = 621), or KRAS G12C ( n = 74) variants were identified. Patients with G12R mutations had longer OS compared with those with G12D overall (12.7 vs. 10.1 months; P value = 0.0001), with similar trends in patients treated with gemcitabine/nab-paclitaxel (13.5 vs. 10.4 months; P value = 0.0002) or FOLFIRINOX (18.3 vs. 14.0 months; P value ARID1A and KMT2D mutations were more frequent in the G12D subgroup. Several genes involved in glucose and glutamine metabolism were less expressed in G12R compared with G12D. PD-L1 expression was lower in G12R compared with G12D (13% vs. 19%). Conclusions: KRAS G12D tumors exhibited a distinct molecular profile compared with G12R tumors, including genes involved in the MAPK pathway, immune activation, and glucose and glutamine metabolism. Patients with G12D mutations had lower OS compared with those with G12R. Based on these data, future studies should address the KRAS mutation status and explore distinct therapeutic vulnerabilities.

Year:

2025

Supplementary Table S3: Comparison of MPAS gene expression between KRAS mutational subgroups. Median values represent transcript per million (TPM). Only genes with trending or significant differences between subgroups are shown. Bold numbers indicate trending (p

Year:

2025

Purpose: 4-1BB (CD137) is a costimulatory immune receptor expressed on activated T cells, activated B cells, NK cells, and tumor-infiltrating lymphocytes, making it a promising target for cancer immunotherapy. Cinrebafusp alfa, a monoclonal antibody-like bispecific protein targeting HER2 and 4-1BB, aims to localize 4-1BB activation to HER2-positive tumors. This study evaluated the safety, tolerability, and preliminary efficacy of cinrebafusp alfa in patients with previously treated HER2-positive malignancies. Patients and Methods: This was a multicenter dose-escalation study involving patients with HER2-positive malignancies who received prior treatment. The study assessed the safety and efficacy of cinrebafusp alfa across various dose levels. Patients were assigned to different cohorts, and antitumor responses were evaluated. The study aimed to determine the MTD and to observe any clinical activity at different dose levels. Results: Of 40 evaluable patients in the “active dose” efficacy cohorts, five showed an antitumor response, resulting in an overall response rate of 12.5% and a disease-control rate of 52.5%. Clinical activity was observed at the 8 and 18 mg/kg dose levels, with confirmed objective response rates of 28.6% and 25.0%, respectively. Cinrebafusp alfa was safe and tolerable, with grade ≤2 infusion-related reactions being the most frequent treatment-related adverse event. MTD was not reached during the study. Conclusions: Cinrebafusp alfa demonstrates promising activity in patients with HER2-positive malignancies who have progressed on prior HER2-targeting regimens. Its acceptable safety profile suggests it could be a treatment option for patients not responding to existing HER2-directed therapies. See related commentary by Eguren-Santamaría et al., p. 231

Year:

2025

Purpose: Transcriptional profiling of pancreatic cancers has defined two main transcriptional subtypes: classical and basal. Initial data suggest shorter survival for patients with basal tumors and differing treatment sensitivity to FOLFIRINOX and gemcitabine plus nab-paclitaxel by transcriptional subtype. Experimental Design: We examined 8,743 patients with RNA sequencing from pancreatic cancers performed at Caris Life Sciences. Classical and basal subtypes were identified using purity independent subtyping algorithm on RNA sequencing, and two cohorts were analyzed: (i) the biomarker cohort included patients with complete molecular profiling data ( n = 7,250) and (ii) the outcome cohort included patients with metastatic disease with available survival outcomes ( n = 5,335). A total of 3,842 patients were shared between the two cohorts. Kaplan–Meier curves and Cox proportional hazards regression were used to assess patient survival. Results: In the biomarker cohort, 3,063 tumors (42.2%) were strongly classical (SC) and 2,015 tumors (27.8%) were strongly basal (SB). SC and SB tumors showed strong associations with histologic phenotypes and biopsy sites. SB tumors had higher rates of KRAS , TP53 , and ARID1A mutations, lower rates of SMAD4 mutation, and transcriptional evidence of epithelial-mesenchymal transition. Sixty of 77 cases (78%) maintained their transcriptional subtype between temporally and/or spatially disparate lesions. In the outcome cohort, the SB subtype was associated with shorter overall survival time, regardless of whether they received FOLFIRINOX or gemcitabine plus nab-paclitaxel as first-line chemotherapy. The mutant KRAS allele type was prognostic of outcomes; however, this impact was restricted to SC tumors, whereas all mutant KRAS alleles had similarly poor outcomes in SB tumors. Conclusions: The SB subtype is a strong independent predictor of worse outcomes, regardless of the up-front chemotherapy regimen used. Clinical trials should further investigate pancreatic cancer transcriptional subtypes as a prognostic and predictive biomarker.

Year:

2024

Purpose: Pure pancreatic acinar cell carcinomas (PACC) are rare malignancies with no established treatment. PACC demonstrates significant genetic intertumoral heterogeneity with multiple pathways involved, suggesting using targeted cancer therapeutics to treat this disease. We aggregated one of the largest datasets of pure PACC to examine the genomic variability and explore patient-specific therapeutic targets. Experimental Design: PACC specimens (n=51) underwent next-generation sequencing (NGS) of DNA (n=29) or whole exome [n=22]) and RNA (whole transcriptome, n=29) at a commercial laboratory. We performed comparative analyses of a genomic cohort of pancreatic ductal adenocarcinomas (PDAC, n=4205). In parallel, we conducted a retrospective review patients with PACC treated at Huntsman Cancer Institute (HCI). Results: The real-world dataset included samples from 51 patients with PACC. We found key molecular differences between pure PACC and PDAC, highlighting the unique characteristics of pure PACC. Major differences in PACC include lower MAPK signaling and less stromal cell abundance compared to PDAC. Pure PACC showed genomic loss-of-heterozygosity to largely coincide with mutations in BRCA1 , BRCA2, and PALB2 . Of the seven patients treated at HCI, one had a tumor that harbored a BRAF -V600E mutation. Leveraging precision oncology, this patient is being treated with encorafenib plus binimetinib, achieving an exceptionally durable and ongoing complete response of more than three years. Conclusions: There are major differences between PACC and PDAC, including downregulation of the MAPK signaling pathway, and less stromal cell abundance. In addition, genomic characterization of pure PACC revealed frequent targetable alterations, which can guide patient treatment.

Year:

2024

Collaborators (31)

Matthew H Bailey

Assistant Professor

Brigham Young University

UNITED STATES
View details

Shunsuke Kondo

Professor

Tokyo Women's Medical University

JAPAN
View details

Alexander Jordan

Assistant Professor

Yale University

UNITED STATES
View details

Stephanie Dougan

Associate Professor

Dana-Farber Cancer Institute

UNITED STATES
View details

George Sledge

-

UNITED STATES
View details

Taroh Satoh

Professor

Osaka University Hospital

JAPAN
View details

Tomoya Yokota

Chief

Aichi Cancer Center

JAPAN
View details

Michael Pishvaian

Associate Professor

Johns Hopkins University

UNITED STATES
View details

Stephen Liu

Associate Professor

Georgetown University School of Medicine

UNITED STATES
View details

Emil Lou

University of Minnesota

UNITED STATES
View details

SANJAY GOEL

Rutgers University

UNITED STATES
View details

James Harding

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Mitesh Borad

Professor of Medicine

Mayo Clinic

UNITED STATES
View details

Paula Pohlmann

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Lipika Goyal

Director of Gastrointestinal Oncology

Stanford University

UNITED STATES
View details

Jashodeep Datta

University of Miami

UNITED STATES
View details

Vaia Florou

Associate Professor

Huntsman Cancer Institute

UNITED STATES
View details

Raja Narayan

Assistant Professor in Surgical Oncology

Loma Linda University

UNITED STATES
View details

Ignacio Garrido-Laguna

University of Utah School of Medicine

UNITED STATES
View details

Sarina Piha-Paul

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Heloisa Soares

Associate Professor

Huntsman Cancer Institute

UNITED STATES
View details

Srivatsan Raghavan

Assistant Professor

Dana-Farber Cancer Institute

UNITED STATES
View details

Joon Oh Park

Sungkyunkwan University School of Medicine

SOUTH KOREA
View details

Teresa Macarulla

Head of Gastrointestinal and Endocrine Tumor Unit

Hospital Clínic de Barcelona

SPAIN
View details

Sara Hurvitz

Professor, Division Head

Washington University School of Medicine

UNITED STATES
View details

Anup Kasi

University of Kansas Cancer Center

UNITED STATES
View details

Anuradha Krishnamurthy

Assistant Professor of Medicine

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Kurt Jaeckle

Professor of Neurology and Oncology

Mayo Clinic Florida

UNITED STATES
View details

Chen Yuan

Assistant Professor

Cedars-Sinai Medical Center

UNITED STATES
View details

Anita Turk

Assistant Professor of Clinical Medicine

-

UNITED STATES
View details

Do-Youn Oh

Professor

Seoul National University Hospital

SOUTH KOREA
View details